The agreement with the EMA on the design of a second confirmatory trial for HyBryte is a significant regulatory milestone for Soligenix. It demonstrates progress in the development of HyBryte and could lead to increased investor confidence in the company's pipeline. This development is likely to be viewed positively by the market, potentially leading to an uptick in SNGX's stock price in the short term.